Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer

Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada

Sun Pharma Canada launches Prwinlevi for treatment for acne

WINLEVI works differently from any other topical acne treatment

Zydus receives final approval from USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System

Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day had annual sales of US $330 million in the United States

USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause

CORONA Remedies collaborates with Ferring Pharmaceuticals to commercialize maternal health & urology products in India

The collaboration between CORONA and Ferring will cater to patients across India

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI

Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer

Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies

NAFLD clinical trial activity catching up in China but lacks substantial domestic participation, says GlobalData

China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Aurigene reports results of AUR101 in phase II study in US patients

AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients